Blog

Daily Archives: May 21, 2013

Zohydro News Update: New Delay

Update on October 25, 2013: The U.S. Food and Drug Administration has approved Zohydro for the management severe chronic pain. According to the FDA press release, Zohydro will be classified as a Schedule II drug with stringent security requirements. The FDA will also conduct postmarketing studies to assess the risk of abuse and addiction. I was … Read More